Acute Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Acute Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001) [Phase 1, Phase 2]
Clinical trial update for BOMedemstat in advanced myeloid malignancies (AML and MDS) across Phase 1/2, with and without ATRA; study status c…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning [Phase 2]
Phase 2 trial update on allogeneic transplantation using timed sequential busulfan and fludarabine conditioning for various hematologic mali…
-
CLINICAL_TRIALS trial_result · 2023-06-29Clinical Trial Update: Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
Phase 1/2 clinical trial assessing a combination regimen including filgrastim, cladribine, cytarabine, mitoxantrone, and sorafenib in newly …
-
FDA approval · 2023-06-28FDA Approved: AZACITIDINE — Original Application (Apotex Corp)
FDA approved Apotex Corp's generic azacitidine (AZACITIDINE) under an original ANDA; the product is indicated for treating certain myelodysp…
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Haplo HCT vs Haplo-cord HCT for Patients With AML [Phase 3]
Phase 3 trial comparing haploidentical hematopoietic stem cell transplantation (haplo HCT) versus haplo-cord HCT in patients with acute myel…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-06-27Clinical Trial Update: Risk-adapted Therapy for Primary Acute Myeloid Leukemia [Phase 2]
A Phase 2 clinical trial update evaluating risk-adapted therapy for primary acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Phase III rhu_GM-CSF + 3 Induction Regimens in Adults With Acute Non-Lymphocytic Leukemia [Phase 3]
Phase III trial evaluating rhu_GM-CSF combined with three induction regimens in adults over 55 with acute non-lymphocytic leukemia has compl…
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Phase 2]
Phase 2 trial comparing three regimens in relapsed or refractory acute myeloid leukemia (AML).
-
EMA withdrawal · 2023-06-21EMA Application withdrawn: Tidhesco (Ivosidenib) — Les Laboratoires Servier
The EMA withdrew the application for Tidhesco (ivosidenib) by Les Laboratoires Servier for acute myeloid leukemia therapeutic use.
-
CLINICAL_TRIALS trial_result · 2023-06-18Clinical Trial Update: A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) [Phase 3]
A global Phase 3 trial evaluating midostaurin plus chemotherapy in newly diagnosed FLT3-mutation negative AML completed with posted results …
-
FDA approval · 2023-06-15FDA Approved: CYTARABINE — Supplemental Application (Meitheal Pharmaceuticals Inc.)
FDA approved a supplemental application for Cytarabine from Meitheal Pharmaceuticals Inc., completing a modification to the existing Cytarab…
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Phase 1]
Phase 1 trial of the oxidative phosphorylation inhibitor IACS-010759 in relapsed or refractory acute myeloid leukemia has been terminated wi…
-
CLINICAL_TRIALS trial_result · 2023-06-15Clinical Trial Update: Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 trial evaluating milademetan tosylate with low-dose cytarabine, with or without venetoclax, in recurrent or refractory acute myelo…
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: Efficacy of 5-Aza for Post-Remission Therapy of Acute Myeloid Leukemia (AML) in Elderly Patients [Phase 3]
A Phase 3 trial update on the efficacy of 5-Aza as post-remission therapy for elderly patients with acute myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML. [Phase 1, Phase 2]
Early-stage study assessing the efficacy and safety of venetoclax in combination with the HAA regimen for newly diagnosed young patients wit…
-
CLINICAL_TRIALS trial_result · 2023-05-30Clinical Trial Update: Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML [Phase 3]
A Phase 3 trial comparing venetoclax plus hypomethylating agent plus aclarubicin versus venetoclax plus HMA in treatment-naive elderly patie…
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS [Phase 2]
Phase 2 trial evaluating nivolumab with oral cyclophosphamide for relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic s…
-
CLINICAL_TRIALS trial_result · 2023-05-26Clinical Trial Update: A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE) [Phase 3]
Phase 3 trial comparing XY0206 to salvage chemotherapy in relapsed or refractory AML with FLT3-ITD mutation (ALIVE).
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia [Phase 3]
Phase 3 randomized, open-label study comparing guadecitabine versus treatment choice in previously treated acute myeloid leukemia has comple…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating combinations including OX40, venetoclax, avelumab, glasdegib, gemtuzumab ozogamicin, and azacitidine in …
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia [Phase 2]
A Phase 2 trial studying temsirolimus added to standard chemotherapy in patients over 60 with acute myeloid leukemia has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease [Phase 2]
Phase 2 clinical trial investigating salsalate, venetoclax, and decitabine or azacitidine for acute myeloid leukemia and advanced myelodyspl…
-
CLINICAL_TRIALS trial_result · 2023-05-24Clinical Trial Update: A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome [Phase 1, Phase 2]
Clinical trial update for IMM01 combined with azacitidine in acute myeloid leukemia and myelodysplastic syndromes, currently in Phase 1 and …
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: Safety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy [Phase 2, Phase 3]
Clinical trial updates on an antifungal showing safety, efficacy, and pharmacokinetics in patients undergoing chemotherapy (Phase 2/Phase 3)…
-
CLINICAL_TRIALS trial_result · 2023-05-10Clinical Trial Update: A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT [Phase 2, Phase 3]
A Phase 2/3 clinical trial evaluating treatments to improve outcomes for adults with acute myeloid leukemia and high-risk myelodysplastic sy…